Sheldon Okada

For the past 20 years, Sheldon Okada has been in the biopharmaceutical industry serving in various commercial and Financial roles while also being passionate about supporting the development and patient access to transformative therapies. He currently serves as the Vice President of Business and Commercial Strategy at Asher Bio. Prior to Asher Bio, he was Senior Director of Commercial Strategy at Forty Seven Inc. (NASDAQ: FTS), where he established the commercial function, supported development strategies, and worked on early launch preparations for their lead program in Oncology.

Earlier in his career, Sheldon spent 14 years at Gilead Sciences in roles of increasing responsibilities within the Commercial Strategy and Financial Planning groups. During his time at Gilead, contributed to the launch of four F.D.A. approved drugs and supported development programs in infectious diseases, liver disease, and inflammation.

Sheldon received his M.S. In Chemistry from the California Institute of technology and a B.A. In Molecular and Cell Biology from the University of California, Berkeley.